

## Matthew E. Hinsch Ph.D.

### Partner

Two Embarcadero Center  
Suite 1900 , San Francisco , CA USA 94111  
t 415.273.7554 | f 415.723.7188  
mhinsch@kilpatricktownsend.com



### Services

Adversarial Patent Prosecution<sup>SM</sup>  
Asset Creation - Prosecution &  
Counseling  
Intellectual Property  
Market Protection - Opinions &  
Dispute Avoidance  
Patents  
Post-Grant Proceedings

### Industries

Energy

Dr. Matthew Hinsch is Co-Leader of Kilpatrick Townsend's Chemistry and Life Sciences practice. Dr. Hinsch's practice concentrates on patent prosecution, primarily within the field of biotechnology. He has advised clients in multiple technical areas, such as genetic modification including CRISPR, immunology and immunotherapy, plant biology, stem cells, disease therapeutics and molecular biology.

In his practice, Dr. Hinsch represents a wide variety of clients, including academic institutions, startup biotechnology and drug discovery companies, and large pharmaceutical companies. He assists clients with patent prosecution, freedom to operate analyses, validity/infringement opinions, IPRs, due diligence reviews and patent portfolio management.

Research for his Ph.D. involved plant molecular biology and the study of the molecular basis of disease resistance in plants.

Dr. Hinsch was recommended by *Legal 500 US* in 2019 and 2021 for Patent Prosecution.

### Education

University of California, Boalt Hall School of Law J.D. (1999)

University of California, Berkeley Ph.D. (1996) Plant Pathology

University of California, San Diego B.A. (1991) Biochemistry

### Admissions



California (1999)

### **Court Admissions**

U.S. Patent and Trademark Office (2001)

### **Insights**

#### [News Releases](#)

Kilpatrick Townsend Receives Top Rankings in 2021 Legal 500 US  
June 14, 2021

#### [News Releases](#)

Kilpatrick Townsend Receives Top Rankings from 2019 Legal 500 US  
July 10, 2019

#### [Events](#)

What You Need to Know When Patenting Antibody Claims  
August 7, 2018

#### [Events](#)

Life Science Industry Panel: New Frontiers of Precision Medicine  
October 12, 2017